Immunology and Neurology Pioneer Dies

Gerald Edelman, who broke new ground in two distinct fields of life science, has passed away at age 84.

By | May 24, 2014

FLICKR, ANDERS ZAKRISSONBiologist Gerald Edelman, who shared the Nobel Prize in physiology or medicine in 1972 for his work on the immune system died this month (May 17). Although the cause of death was unclear, Edelman had prostate cancer and Parkinson’s disease. He was 84.

Edelman discovered that antibodies were made of two peptide chains—one long and one short—instead of one long peptide chain, as was once thought. Starting in the mid-1970s, Edelman shifted his research focus to the brain. He developed a theory that neuronal groups were selected for much like Darwinian selection produces certain phenotypes. He had previously found that antibody selection worked this way. The theory was controversial, but has been supported by subsequent research findings.

“There isn’t going to be any kind of theory of the brain that doesn’t involve elements of his ideas,” Peter Vanderklish, a neuroscientist and colleague of Edelman’s at the Scripps Research Institute in La Jolla, California, told The New York Times. “The brain is never—never has been or ever will be—in the same state twice, and will never encounter the same environmental cues twice. What’s attractive about his model is that it tries to address that reality.”

Edelman is survived by his wife, two sons, and daughter.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. First In Vivo Function Found for Animal Circular RNA
  2. Your Body Is Teeming with Weed Receptors
    Features Your Body Is Teeming with Weed Receptors

    And the same endocannabinoid system that translates marijuana's buzz-inducing compounds into a high plays crucial roles in health and disease outside the brain.

  3. Opinion: We Need a Replacement for Beall’s List
  4. Doctors’ Advice to Finish Antibiotics Overlooks Resistance
AAAS